Infectious Diseases (all articles)
‘Super antigens’ tied to mysterious COVID-19 syndrome in children
21 Oct, 2020 | 09:21h | UTC‘Super antigens’ tied to mysterious COVID-19 syndrome in children – National Geographic
Perspective: COVID-19 in children and young people
21 Oct, 2020 | 09:17h | UTCCOVID-19 in children and young people – Science
Updated Guideline: Coronavirus (COVID-19) infection in pregnancy
21 Oct, 2020 | 09:16h | UTCCoronavirus (COVID-19) Infection in Pregnancy – Royal College of Obstetricians & Gynaecologists
Clinical Report: Evaluation and management of the infant exposed to HIV in the US
21 Oct, 2020 | 09:09h | UTCEvaluation and Management of the Infant Exposed to HIV in the United States – Pediatrics
Commentaries: Pediatrics Group Updates Guidelines on Managing HIV-Exposed Infants – NEJM Journal Watch AND Perinatal Exposure to HIV Requires Specialized, Coordinated Care – AJMC
Covid-19: The global crisis — in data
20 Oct, 2020 | 01:45h | UTCCovid-19: The global crisis — in data – Financial Times
WHO takes a position on genetically modified mosquitoes
21 Oct, 2020 | 09:02h | UTCWHO takes a position on genetically modified mosquitoes – World Health Organization
Position Statement: Evaluation of genetically modified mosquitoes for the control of vector-borne diseases – World Health Organization
Editorial: Covid-19’s known unknowns
20 Oct, 2020 | 01:42h | UTCCovid-19’s known unknowns – The BMJ
Commentary on Twitter
If you are going to read anything today let it be this short editorial @bmj_latest https://t.co/ggvEglehJm pic.twitter.com/hyw21BcZBU
— Maarten van Smeden (@MaartenvSmeden) October 19, 2020
Covid-19 vaccine protocols reveal that trials are designed to succeed
20 Oct, 2020 | 01:40h | UTCCovid-19 Vaccine Protocols Reveal That Trials Are Designed To Succeed – Forbes
Herd immunity and implications for SARS-CoV-2 control
20 Oct, 2020 | 01:44h | UTCHerd Immunity and Implications for SARS-CoV-2 Control – JAMA
Author Interview: Can We Count on Herd Immunity to Control COVID-19? – JAMA
Patient Page: What Is Herd Immunity? – JAMA
Commentary on Twitter
Herd immunity is real. It may be inevitable given our poor handling of COVID-19 and nature of the virus.
But to *deliberately* shoot for natural herd immunity (ie, without a vaccine) makes no sense.
Via @SaadOmer3 @InciYildirim11 @thehowie @JAMA_current https://t.co/PwWc1wMMzE pic.twitter.com/Ybn7vHFnt8
— Nicholas A. Christakis (@NAChristakis) October 19, 2020
Antimicrobial stewardship in ICUs during the COVID-19 pandemic: back to the 90s?
20 Oct, 2020 | 01:38h | UTC
Commentary on Twitter
Side effect of #COVID19 surge: ignoring well established strategies
➡️ limit ABTs exposure vs resistances: MV/long #ICU stay
➡️ avoid toxicity: antivirals/antibiotics can have severe adverse effects/interactions
➡️ high mortality: improving outcome crucial https://t.co/FN3LtKKlsr pic.twitter.com/7KGbIOH3Uf— Intensive Care Medicine (@yourICM) October 17, 2020
Opinion: The scientific and ethical feasibility of immunity passports
20 Oct, 2020 | 01:41h | UTCThe scientific and ethical feasibility of immunity passports – The Lancet Infectious Diseases
Related: Digital ‘health passport’ trials under way to aid reopening of borders – The Guardian
The household secondary attack rate of SARS-CoV-2: A rapid review
20 Oct, 2020 | 01:36h | UTCThe household secondary attack rate of SARS-CoV-2: A rapid review – Clinical Infectious Diseases
Commentary on Twitter
Household secondary attack rate (SAR) of #SARSCoV2 A rapid review https://t.co/u2YGZYB9Zt The overall pooled random-effects estimate of the household SAR was 17.1% (95% CI: 13.7-21.2%). Household SAR higher among older adult contacts and among contacts of symptomatic cases.
— Carlos del Rio (@CarlosdelRio7) October 16, 2020
Perspective: All eyes on a hurdle race for a SARS-CoV-2 vaccine
20 Oct, 2020 | 01:39h | UTCAll eyes on a hurdle race for a SARS-CoV-2 vaccine – Nature
Meta-analysis: The association of D-dimers with mortality, intensive care unit admission or ARDS in patients hospitalized with COVID-19
20 Oct, 2020 | 01:37h | UTC
Vertical transmission of Zika virus and its outcomes: a Bayesian synthesis of prospective studies
20 Oct, 2020 | 01:30h | UTCCommentary: Desideratum: a developmentalist view of Zika virus infection – The Lancet Infectious Diseases
Plastic surgery complications: A review for emergency clinicians
20 Oct, 2020 | 01:32h | UTC
[Preprint] Multi-organ impairment in low-risk individuals with long COVID
18 Oct, 2020 | 23:18h | UTCMulti-organ impairment in low-risk individuals with long COVID – medRxiv
Related study (preprint): Persistent symptoms after Covid-19: qualitative study of 114 long Covid patients and draft quality criteria for services – medRxiv
Commentary on Twitter
"In a young, low-risk population with ongoing symptoms, almost 70% of individuals have impairment in 1 or more organs 4 months after initial symptoms of #SARSCoV2 infection" #LongCovid https://t.co/gPnDtacI1J by @amibanerjee1 and colleagues
via @ahandvanish<-🙏 pic.twitter.com/7mKEsQgq5l— Eric Topol (@EricTopol) October 17, 2020
WHO: Herd immunity, lockdowns and COVID-19
18 Oct, 2020 | 23:19h | UTCCoronavirus disease (COVID-19): Herd immunity, lockdowns and COVID-19 – World Health Organization
Commentary on Twitter
Herd immunity is a concept used for vaccination, in which a population can be protected from a virus if a threshold of vaccination is reached. Vaccinated people are protected from getting the disease & passing it on, breaking any chains of transmission.
👉https://t.co/X9N7zcyfOX pic.twitter.com/V22iA6OqOq
— World Health Organization (WHO) (@WHO) October 16, 2020
New studies show reduced prevalence and severity of SARS-CoV-2 infection in ABO blood group O
18 Oct, 2020 | 23:16h | UTCStudy 1: Reduced prevalence of SARS-CoV-2 infection in ABO blood group O – Blood Advances
Commentaries: People with blood type O may have lower risk of Covid-19 infection and severe illness, two new studies suggest – CNN AND Studies offer new evidence for possible link between blood type and COVID-19 susceptibility – American Society of Hematology
Answering key questions about COVID-19 vaccines
18 Oct, 2020 | 23:10h | UTCAnswering Key Questions About COVID-19 Vaccines – JAMA
Commentary on Twitter
Many individuals are hesitant about receiving #COVID19 vaccines. It is critical that clinicians stay well informed about emerging data so that they can help patients make sound decisions https://t.co/1QDwOKuDqc @JesseGoodmanMD @ImmunizeOrg @pharmacists
— JAMA (@JAMA_current) October 16, 2020
NIHR dynamic review of the evidence around ongoing Covid19 symptoms (often called Long Covid)
18 Oct, 2020 | 23:14h | UTCA dynamic review of the evidence around ongoing Covid19 symptoms (often called Long Covid) – National Institute for Health Research
News Release: Living with COVID: NIHR publishes dynamic themed review into ‘ongoing COVID’
Commentaries: Coronavirus: ‘Long Covid could be four different syndromes’ – BBC AND Long covid could be four different syndromes, review suggests – The BMJ AND ‘Long COVID’ may affect multiple parts of body and mind, doctors say – Reuters
Postlicensure evaluation of COVID-19 Vaccines
18 Oct, 2020 | 23:08h | UTCPostlicensure Evaluation of COVID-19 Vaccines – JAMA
Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes
18 Oct, 2020 | 23:07h | UTC
Commentary on Twitter
The cytokine storm of severe #COVID19 and how it differs from ARDS, sepsis, and CAR-T cytokine release syndrome. Best review to date on this ★
Today @LancetRespirMed https://t.co/BOUjvIOWLi @danleisman @Poietic_Justice @IcahnMountSinai @CDMD62
🙏 for pulling all this together pic.twitter.com/qZCPbrxvYU— Eric Topol (@EricTopol) October 16, 2020
[Preprint] WHO SOLIDARITY trial results published; Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon do not improve outcomes in Covid-19
16 Oct, 2020 | 09:42h | UTCRepurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results – medRxiv
Commentary: Remdesivir and interferon fall flat in WHO’s megastudy of COVID-19 treatments – Science
Commentaries on Twitter
Results of the @WHO SOLIDARITY trial:
4 drugs tested in 11,266 patients with COVID in 405 hospitals in 30 countries:
– hydroxychloroquine
– lopinavir
– remdesevir
– interferonNo clear benefit of any of them on survival. https://t.co/ohtTAFaSnc pic.twitter.com/2fO9E8zs8h
— Martin Landray (@MartinLandray) October 16, 2020
This is blockbuster from @WHO: 'Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens have little or no effect on hospitalized COVID-19, as indicated by mortality, initiation of ventilation and duration of hospital stay. @medrxivpreprint https://t.co/aNGLzLL5uW pic.twitter.com/daOAMVW62u
— Harlan Krumholz (@hmkyale) October 15, 2020
Scientific consensus on the COVID-19 pandemic: we need to act now
16 Oct, 2020 | 09:41h | UTCScientific consensus on the COVID-19 pandemic: we need to act now – The Lancet